Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, Roth Capital downgraded Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. View Our Latest […]
More Stories
DeFiChain (DFI) Trading 25% Lower Over Last 7 Days
DeFiChain (DFI) traded 5.8% higher against the US dollar during the 24-hour period ending at 10:00 AM ET on December...
UBS Group Issues Pessimistic Forecast for NIKE (NYSE:NKE) Stock Price
NIKE (NYSE:NKE – Get Free Report) had its target price reduced by equities research analysts at UBS Group from $80.00...
Centurion (CNT) Price Hits $0.0010
Centurion (CNT) traded 3% lower against the US dollar during the 24-hour period ending at 10:00 AM Eastern on December...
Stifel Nicolaus Forecasts Strong Price Appreciation for FactSet Research Systems (NYSE:FDS) Stock
FactSet Research Systems (NYSE:FDS – Get Free Report) had its price objective boosted by research analysts at Stifel Nicolaus from...
PotCoin (POT) Trading 37.3% Lower Over Last Week
PotCoin (POT) traded 22.1% lower against the dollar during the twenty-four hour period ending at 10:00 AM Eastern on December...
My DeFi Pet One Day Trading Volume Hits $41,393.20 (DPET)
My DeFi Pet (DPET) traded down 13.1% against the U.S. dollar during the 24 hour period ending at 10:00 AM...